9:00 am Regulatory and Clinical Considerations for LBPs

9:30 am Updates from the Microbiome Therapeutics Innovation Group (MTIG) – Building a Collective Voice to Enhance the Regulatory, Investment and Commercial Success of Microbiome-Based Therapeutics

10:00 am Meeting the Supply Needs of the Microbiome Sector

10:30 am A Trifecta in Microbiome Advancements: Expectations from the Partnership of Diversigen, Corebiome and DNA Genotek

11.00am Morning Refreshments and Speed Networking

Track A: Pre-Clinical Development & Mechanistic Analysis of Microbiome-based Therapeutics

Track B: Clinical Translation, Manufacturing and Commercialization of Microbiome-based Therapeutics

Track C: Microbiome-based Biomarkers, Bioinformatics and Patient Stratification

Introducing the Era of Engineered Microbes


11.30 Genetically Engineered Microbial Medicines (GEMMs) for the Treatment of Chronic Diseases

Will DeLoache, Co-Founder & CSO, Novome Biotechnologies



12.00 Preclinical Development of Live Biotherapeutics to Treat Chronic Lung Infections

Stacy Townsend, Director of Pre-Clinical Development, SciBac



12.30 Delivery of Biomolecules to the Mammalian Gut Using Engineered Probiotic Saccharomyces Boulardii

Nathan Crook, Assistant Professor – Chemical & Biomolecular Engineering, NC State

Manufacturing and Scaling the Microbiome Continued


11.30 Building a Strategic Partnership to Effectively Scale and Manufacture Microbiome-based Therapeutics

Adrien Nivoliez, CEO, Biose Industrie

Chris Reyes, Co-Founder & CEO, Bloom Science


12.00 How to Lyophilize a Live Bacteriotherapeutic Product? 

Yogesh Mudaliar, Research Investigator Drug Product Development, Takeda Pharmaceuticals


12.30 Clinical Development for the First and Only Medical Probiotic for People with Type 2 Diabetes

Colleen Cutcliffe, Co-founder & CEO, Pendulum Therapeutics


12.45 The Microbes in our Food and Their Potential to Become Health Solutions

Gerardo Toledo, Co-Founder & CEO, Solarea Bio

Microbiome Drug Metabolism


11.30 Human Microbiome Signatures of Differential Drug Metabolismt

Libusha Kelly, Associate Professor, Albert Einstein College of Medicine




12.00 Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?

Nikki Klatt, Associate Professor Pediatrics, University of Miami



12.30 Studying Drug-Microbiome Interactions Using Metformin

Hariom Yadav, Assistant Professor, Molecular Medicine, Wake Forest School of Medicine

1.00 pm Lunch and Networking

Subtractive Therapeutics that Target the Human Microbiome


14.00 Customized Phage Therapies for Chronic Disease

Assaf Oron, Chief Business Officer, BiomX



14.30 No GUS, No Glory: Microbiome-Targeted Small Molecule Drugs to Prevent NSAID-Induced Intestinal Injury

Jeffrey Hymes, Scientist, Symberix



15.00 Developing CRISPR-based Microbiome Drugs to Selectively Eradicate Target Bacteria

Eric Van der Helm, Head of Synthetic Biology & Bioinformatics, SNIPR Biome



15.30 Progress in Antibody-Mediated Modulation of Microbiome Event Cascades

Julius Goepp, Founder & CEO, Scaled Microbiomics

14.00 Gut-Brain axis mechanism of action and Clinical results on a new probiotic strain for the regulation of appetite and weight management

Gregory Lambert, CEO and VP R&D, TargEDys


14.15 Commercialisation of Microbiota-based Products: Food or Pharma – Pro’s and Con’s  

Luc Sterkman, CEO, Caelus Health


14.30 Panel Discussion 

Moderator: Mohan Iyer, Chief Operating Officer, Pendulum Therapeutics


Luc Sterkman, CEO, Caelus Health

Gregory Lambert, CEO and VP R&D, TargEDys

Gerardo Toledo, Co-Founder & CEO, Solarea Bio

Colleen Cutcliffe, Co-founder & CEO, Pendulum Therapeutics


Collaborations & Initiatives to Drive Commercial Success


15.00 Targeting the Microbiome to Intercept Diseases

Dirk Gevers, Global Head, Janssen Human Microbiome Institut


15.30 Presentation from Wacker Biotech

Challenges of Bioinformatics & Data Integration


14.00 Reviewing Data Integration Using Microbiome Insights

Gunjan Singh Thakur, Senior Scientist Computational Biology, Merck Exploratory Science Center



14.30 The Human Microbiome Outperforms Genome-wide Association Studies in Predicting Human Disease

Alexander Kostic, Assistant Professor, Harvard Medical School



15.00 Building Bioinformatic Models to Translate the Human Microbiome into Actionable Diagnostics & Therapeutics

Yangcong Zhang, Postodoctoral Fellow Huttenhower Lab, Harvard T.H. Chan School of Public Health

4:00 pm Close of 5th Microbiome Movement – Drug Development Summit 2020